150 related articles for article (PubMed ID: 22825518)
1. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
2. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
4. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
Kulke MH
J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
[No Abstract] [Full Text] [Related]
5. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
[TBL] [Abstract][Full Text] [Related]
6. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
7. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
[TBL] [Abstract][Full Text] [Related]
9. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
10. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Benavent M; de Miguel MJ; Garcia-Carbonero R
Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib still fi rst-line therapy for metastatic renal cancer.
Bagcchi S
Lancet Oncol; 2014 Sep; 15(10):e420. PubMed ID: 25328943
[No Abstract] [Full Text] [Related]
12. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Crippa S; Partelli S; Boninsegna L; Falconi M
Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
[No Abstract] [Full Text] [Related]
13. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.
Yao JC; Lagunes DR; Kulke MH
Oncologist; 2013; 18(5):525-32. PubMed ID: 23615698
[TBL] [Abstract][Full Text] [Related]
15. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):135-8. PubMed ID: 20208321
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
18. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
19. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
Broder MS; Chang E; Reddy SR; Neary MP
Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129
[TBL] [Abstract][Full Text] [Related]
20. Translational medicine: Cancer lessons from mice to humans.
Tuveson D; Hanahan D
Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
